Trails Edge Capital Partners’s First Tracks Biotherapeutics TRAX Stock Holding History

Trails Edge Capital Partners’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.5M	Buy	+1,514,000	New	+$28.3M	4.84%	4

Other funds holding TRAX

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Trails Edge Capital Partners's TRAX Position: Q2 2026 in Review

Trails Edge Capital Partners opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 1,514,000 shares worth $30.5M. The stake represents 4.84% of the portfolio and ranks #4 among its holdings.

136 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Trails Edge Capital Partners held 1,514,000 shares of First Tracks Biotherapeutics worth $30.5M as of Q2 2026.
First Tracks Biotherapeutics was a new Trails Edge Capital Partners position in Q2 2026.
First Tracks Biotherapeutics made up 4.84% of Trails Edge Capital Partners's portfolio in Q2 2026, its #4 holding.
136 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.